A review of endemic mycoses after hematopoietic stem cell transplantation.
coccidioides
endemic fungi
hematopoietic transplantation
histoplasma
talaromyces
Journal
Transplant infectious disease : an official journal of the Transplantation Society
ISSN: 1399-3062
Titre abrégé: Transpl Infect Dis
Pays: Denmark
ID NLM: 100883688
Informations de publication
Date de publication:
14 Sep 2023
14 Sep 2023
Historique:
revised:
01
09
2023
received:
21
08
2023
accepted:
06
09
2023
medline:
14
9
2023
pubmed:
14
9
2023
entrez:
14
9
2023
Statut:
aheadofprint
Résumé
Endemic mycoses after hematopoietic stem cell transplantation (HSCT) are rarely reported. We aimed to comprehensively review the clinical presentation and outcomes of endemic mycoses in this immunocompromised population. Multiple databases were reviewed from inception through May 31, 2023 using endemic fungi as keywords (e.g., coccidioides, histoplasma, blastomyces, talaromyces, and paracoccidioides). Only hematopoietic transplants were included. There were 16 publications on endemic mycoses after HSCT that reported nine unique cases of histoplasmosis, seven coccidioidomycosis, and two talaromycosis. No cases of paracoccidioides and blastomycoses were identified. Fifteen cases were allogeneic hematopoietic transplant recipients and three were autologous. Many were male (14/18, 77.8%) and overall median age was 50 (range 21-75) years. Among the 16 patients with coccidiodomycosis or histoplasmosis, fever, cytopenias and disseminated disease were the most common clinical presentations, with median onset of 8 or 12 months after HSCT, respectively. Likewise, the two HSCT patients with talaromycosis presented with disseminated disease at 12 and 48 months after transplantation. The vast majority were not on effective azole prophylaxis at the time of presentation, and many had recent intensification of immunosuppression. Nine of 18 patients died (50%), and all deaths occurred among patients with disseminated endemic mycoses. Endemic mycoses among HSCT are uncommon. Onset was late, after discontinuation of azole prophylaxis, or was associated with intensification of immunosuppression. Disseminated disease was a common presentation, manifested by fever and cytopenias. Attributable mortality was high, and emphasizes the need for a high index of clinical suspicion so that prompt diagnosis and treatment is provided.
Sections du résumé
BACKGROUND
BACKGROUND
Endemic mycoses after hematopoietic stem cell transplantation (HSCT) are rarely reported. We aimed to comprehensively review the clinical presentation and outcomes of endemic mycoses in this immunocompromised population.
METHODS
METHODS
Multiple databases were reviewed from inception through May 31, 2023 using endemic fungi as keywords (e.g., coccidioides, histoplasma, blastomyces, talaromyces, and paracoccidioides). Only hematopoietic transplants were included.
RESULTS
RESULTS
There were 16 publications on endemic mycoses after HSCT that reported nine unique cases of histoplasmosis, seven coccidioidomycosis, and two talaromycosis. No cases of paracoccidioides and blastomycoses were identified. Fifteen cases were allogeneic hematopoietic transplant recipients and three were autologous. Many were male (14/18, 77.8%) and overall median age was 50 (range 21-75) years. Among the 16 patients with coccidiodomycosis or histoplasmosis, fever, cytopenias and disseminated disease were the most common clinical presentations, with median onset of 8 or 12 months after HSCT, respectively. Likewise, the two HSCT patients with talaromycosis presented with disseminated disease at 12 and 48 months after transplantation. The vast majority were not on effective azole prophylaxis at the time of presentation, and many had recent intensification of immunosuppression. Nine of 18 patients died (50%), and all deaths occurred among patients with disseminated endemic mycoses.
CONCLUSION
CONCLUSIONS
Endemic mycoses among HSCT are uncommon. Onset was late, after discontinuation of azole prophylaxis, or was associated with intensification of immunosuppression. Disseminated disease was a common presentation, manifested by fever and cytopenias. Attributable mortality was high, and emphasizes the need for a high index of clinical suspicion so that prompt diagnosis and treatment is provided.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14155Informations de copyright
© 2023 Wiley Periodicals LLC.
Références
Mellinghoff SC, Panse J, Alakel N, et al. Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). Ann Hematol. 2018;97(2):197-207.
Agrawal V, Brinda BJ, Farag SS. Histoplasma capsulatum infection in an allogeneic hematopoietic stem cell transplant patient receiving voriconazole prophylaxis. Case Rep Hematol. 2020;2020:8024137.
Atalay A, Koc AN, Akyol G, Cakir N, Kaynar L, Ulu-Kilic A. Pulmonary infection caused by Talaromyces purpurogenus in a patient with multiple myeloma. Infez Med. 2016;24(2):153-157.
Glenn TJ, Blair JE, Adams RH. Coccidioidomycosis in hematopoietic stem cell transplant recipients. Med Mycol. 2005;43(8):705-710.
Haydoura S, Wallentine J, Lopansri B, Ford CD, Saad D, Burke JP. Disseminated histoplasmosis in allogeneic bone marrow transplant: a diagnosis not to be missed. Transplant Infect Dis. 2014;16(5):822-826.
Honarpisheh HH, Curry JL, Richards K, et al. Cutaneous histoplasmosis with prominent parasitization of epidermal keratinocytes: report of a case. J Cutan Pathol. 2016;43(12):1155-1160.
Jones O, Cleveland KO, Gelfand MS. A case of disseminated histoplasmosis following autologous stem cell transplantation for Hodgkin's lymphoma: an initial misdiagnosis with a false-positive serum galactomannan assay. Transplant Infect Dis. 2009;11(3):281-283.
Manning MA, Kuo PH, Yeager AM. Disseminated coccidioidomycosis masquerading as recurrent lymphoma. BMJ Case Rep. 2018;2018:bcr2018224965.
Mohan M, Fogel B, Eluvathingal T, Schinke C, Kothari A. Gastrointestinal histoplasmosis in a patient after autologous stem cell transplant for multiple myeloma. Transplant Infect Dis. 2016;18(6):939-941.
Multani A, Allard LS, Wangjam T, et al. Missed diagnosis and misdiagnosis of infectious diseases in hematopoietic cell transplant recipients: an autopsy study. Blood Adv. 2019;3(22):3602-3612.
Natarajan M, Swierzbinski MJ, Maxwell S, et al. Pulmonary histoplasma infection after allogeneic hematopoietic stem cell transplantation: Case report and review of the literature. Open Forum Infect Dis. 2017;4(2):ofx041.
Riley DK, Galgiani JN, O'Donnell MR, Ito JI, Beatty PG, Evans TG. Coccidioidomycosis in bone marrow transplant recipients. Transplantation. 1993;56(6):1531-1533.
Rodriguez JA, Ivancic S, Eckardt PA, Lemos-Ramirez JC, Niu J. A case of pulmonary histoplasmosis presenting with hypercalcemia and altered mental status in a patient following allogeneic hematopoietic stem cell transplantation. Am J Case Rep. 2020;21:e919724.
Sahoo MK, Tripathi M, Deepak R, Gupta RK, Damle N, Bal C. Disseminated histoplasmosis demonstrated on F18-fluorodeoxyglucose positron emission tomography/computed tomography in a renal transplant recipient. Indian J. 2016;31(2):162-164.
Saling CF, Gea-Banacloche J, Trickett JS, Blair JE. Coccidioidomycosis in allogeneic stem cell transplant recipients: case series and review of the literature. J Fungi. 2021;7(5):27.
Walsh TJ, Catchatourian R, Cohen H. Disseminated histoplasmosis complicating bone marrow transplantation. Am J Clin Pathol. 1983;79(4):509-511.
Woo PC, Lau SK, Lau CC, et al. Penicillium marneffei fungaemia in an allogeneic bone marrow transplant recipient. Bone Marrow Transplant. 2005;35(8):831-833.
Castro-Lopez N, Hung CY. Immune response to coccidioidomycosis and the development of a vaccine. Microorganisms. 2017;5(1):13.
Kimes KE, Kasule SN, Blair JE. Pulmonary Coccidioidomycosis. Semin Respir Crit Care Med. 2020;41(1):42-52.
Alexander BD, Lamoth F, Heussel CP, et al. Guidance on Imaging for invasive pulmonary aspergillosis and mucormycosis: from the imaging working group for the revision and update of the consensus definitions of fungal disease from the EORTC/MSGERC. Clin Infect Dis. 2021;72(2):S79-S88.
Wheat LJ, Hackett E, Durkin M, et al. Histoplasmosis-associated cross-reactivity in the BioRad Platelia Aspergillus enzyme immunoassay. Clin Vaccine Immunol. 2007;14(5):638-640.
Vergidis P, Walker RC, Kaul DR, et al. False-positive Aspergillus galactomannan assay in solid organ transplant recipients with histoplasmosis. Transplant Infect Dis. 2012;14(2):213-217.